Novo Nordisk’s Fiasp product enters the user’s bloodstream two times faster than NovoRapid and is designed to match a healthy body’s response to a meal, according to Insulet.
“The addition of Fiasp for use with the Omnipod System provides another option for both patients and prescribers to support their diabetes management needs,” DJ Cass, GM of Insulet’s Europe unit, said in prepared remarks.
“It is encouraging to see that Fiasp keeps expanding its reach, potentially benefiting more people in need of it via the Insulet Omnipod System,” Stephen Gough, Novo Nordisk’s global CMO, added. “With its ultra-fast acting profile, Fiasp has brought a new option for adults living with diabetes who require insulin to manage their post-meal spikes, and I am confident that they will find in Fiasp and the Omnipod System good allies to best manage their diabetes.”
Earlier this year, Insulet assumed direct commercial operations in Europe for its Omnipod tubeless insulin pump.
The Billerica, Mass.-based company first announced it would part ways with its former European distributor, Ypsomed, in July last year. Insulet has since established a team of more than 100 employees to take care of distributing and selling its Omnipod system in Europe, the company reported.